ArticleJournal of the American Heart Association2022
Differences in Prognosis and Cardiac Function According to Required Percutaneous Mechanical Circulatory Support and Histological Findings in Patients With Fulminant Myocarditis: Insights From the CHANGE PUMP 2 Study.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Global epidemiology of myocarditis: disparities in age, sex and geography.Nature reviews. Cardiology · 2026Review
- Acute Myocarditis: From Pathophysiology to Risk-Stratified Management-A Clinical Review.European journal of clinical investigation · 2026Review
- Post-viral myocarditis.Heart failure reviews · 2026Review
- Acute and Chronic Myocarditis in Men and Women.Current heart failure reports · 2026Review
- T cells in acute and chronic myocarditis: from diagnosis to treatment.European heart journal · 2026Review
- Temporary mechanical support in fulminant myocarditis: prognostic factors and clinical implications from the FULLMOON study.Intensive care medicine · 2026Article
- Cardiogenic Shock Management in the Modern Era: A Narrative Review of Percutaneous Mechanical Circulatory Support Devices.Journal of cardiovascular development and disease · 2025Review
- Long-term left ventricular ejection function in fulminant and non-fulminant myocarditis: A multicenter study in China.International journal of cardiology. Heart & vasculature · 2025Article
- Exploring Strategies to Improve Outcomes in Patients With Giant Cell Myocarditis: A Case Series of Five Biopsy-Proven Cases.Journal of Korean medical science · 2025Article
- Diagnosis and management of patients with fulminant myocarditis.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- A comparative review of myocarditis in pediatrics versus adults: pathogenesis, diagnosis, and management.Frontiers in immunology · 2025Review
- Lactate Dehydrogenase Indicates Development From Fulminant Myocarditis to Chronic Persistent Myocarditis: A Multicenter Retrospective Cohort Study in China.International journal of general medicine · 2025Article
- Angiotensin-Converting Enzyme Inhibitors Mitigate Development of Chronic Persistent Cardiac Dysfunction Following Fulminant Myocarditis: A Multicenter Retrospective Study in China.International journal of general medicine · 2025Article
- Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis.Science China. Life sciences · 2024Review
- Changes in Cardiac Function Following Fulminant Myocarditis.Circulation. Heart failure · 2024Article
- Fulminant Myocarditis Temporally Associated with COVID-19 Vaccination.Current cardiology reports · 2024Review
- Bridging fulminant myocarditis patients to recovery or advanced therapies with veno-arterial extracorporeal membrane oxygenation: a single-center retrospective study.World journal of emergency medicine · 2024Article
- Exosomes and their derivatives as biomarkers and therapeutic delivery agents for cardiovascular diseases: Situations and challenges.Journal of translational internal medicine · 2023Article
- Myocarditis: a primer for intensivists.Intensive care medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Prognoses and long-term cardiac function of patients with fulminant myocarditis have not been fully elucidated. Therefore, we clarified the prognoses and long-term cardiac function according to required percutaneous mechanical circulatory support and histological findings among patients with fulminant myocarditis. Methods and Results We conducted a multicenter retrospective medical record review of 216 patients with fulminant myocarditis requiring percutaneous mechanical circulatory support. Sixty-one patients were treated with intra-aortic balloon pump or Impella alone, and 155 patients received veno-arterial extracorporeal membrane oxygenation and were treated with or without intra-aortic balloon pump or Impella. Histologically, 107 patients had lymphocytic myocarditis; 34, eosinophilic myocarditis; and 4, giant cell myocarditis. Freedom from composite end point (death, durable left ventricular assist device implantation, and heart transplantation) was 66% at 90 days, 62% at 1 year, and 57% at 6 years. Veno-arterial extracorporeal membrane oxygenation use was associated with poor prognosis in the multivariable analysis (hazard ratio [HR], 5.27; 95% CI, 1.60-17.36). The eosinophilic myocarditis subgroup showed better prognosis (HR, 0.28; 95% CI, 0.10-0.80) compared with the lymphocytic myocarditis subgroup but not in the multivariable analysis. Ventricular tachycardia/ventricular fibrillation rhythm at admission, high C-reactive protein level, and no endomyocardial biopsy were also associated with poor prognosis. The left ventricular ejection fraction at 1 year was ≤50% in 16% of patients and was lower in patients with eosinophilic myocarditis (median: 57.9% [48.8-65.0%]) than in those with lymphocytic myocarditis (65.0% [58.6-68.7%]) (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.